グレーブス眼症は、甲状腺が有害な細胞を誤って感知し、それらと戦うために抗体を放出する自己免疫疾患です。有害な細胞がないため、放出された抗体が目の筋肉と融合し、グレーブス眼症を発症します。症状には、目の充血、目の炎症、まぶたの収縮、目の衰弱などがあります。 治療には、放射性ヨウ素療法、抗甲状腺薬、甲状腺手術が含まれます。
目次
Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Graves' Ophthalmopathy - Overview
Graves' Ophthalmopathy - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Graves' Ophthalmopathy - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Graves' Ophthalmopathy - Companies Involved in Therapeutics Development
Graves' Ophthalmopathy - Drug Profiles
Graves' Ophthalmopathy - Dormant Projects
Graves' Ophthalmopathy - Discontinued Products
Graves' Ophthalmopathy - Product Development Milestones
Featured News & Press Releases
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Graves' Ophthalmopathy, 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Universities/Institutes, 2022
Products under Development by Companies, 2022
Products under Development by Companies, 2022 (Contd..1)
Products under Development by Universities/Institutes, 2022
Number of Products by Stage and Target, 2022
Number of Products by Stage and Mechanism of Action, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Graves' Ophthalmopathy - Pipeline by advanceCor GmbH, 2022
Graves' Ophthalmopathy - Pipeline by Enceladus Pharmaceuticals BV, 2022
Graves' Ophthalmopathy - Pipeline by Eye Bio Korea Co Ltd, 2022
Graves' Ophthalmopathy - Pipeline by Genmab AS, 2022
Graves' Ophthalmopathy - Pipeline by GSK plc, 2022
Graves' Ophthalmopathy - Pipeline by HanAll Biopharma Co Ltd, 2022
Graves' Ophthalmopathy - Pipeline by ImmunoGen Inc, 2022
Graves' Ophthalmopathy - Pipeline by Innovent Biologics Inc, 2022
Graves' Ophthalmopathy - Pipeline by Jiangsu Hengrui Medicine Co Ltd, 2022
Graves' Ophthalmopathy - Pipeline by Novartis AG, 2022
Graves' Ophthalmopathy - Pipeline by Pierre Fabre Pharmaceuticals Inc, 2022
Graves' Ophthalmopathy - Pipeline by Regeneron Pharmaceuticals Inc, 2022
Graves' Ophthalmopathy - Pipeline by RevOpsis Therapeutics Corp, 2022
Graves' Ophthalmopathy - Pipeline by Sling Therapeutics Inc, 2022
Graves' Ophthalmopathy - Pipeline by Suzhou Pulekang Pharmaceutical Technology Co Ltd, 2022
Graves' Ophthalmopathy - Pipeline by Viridian Therapeutics Inc, 2022
Graves' Ophthalmopathy - Dormant Projects, 2022
List of Figures
Number of Products under Development for Graves' Ophthalmopathy, 2022
Number of Products under Development by Companies, 2022
Number of Products by Top 10 Targets, 2022
Number of Products by Stage and Top 10 Targets, 2022
Number of Products by Top 10 Mechanism of Actions, 2022
Number of Products by Stage and Top 10 Mechanism of Actions, 2022
Number of Products by Top 10 Routes of Administration, 2022
Number of Products by Stage and Top 10 Routes of Administration, 2022
Number of Products by Top 10 Molecule Types, 2022
Number of Products by Stage and Top 10 Molecule Types, 2022
